Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline

Coronary Disease: full-pipeline trial registry

1 of 36 indexed Coronary Disease trials are currently recruiting.

Corpus placement: #419 of 28,707 conditions by registered trial count.

36 US clinical trials · 1 currently recruiting · #419 of 28,707 conditions by registered trial count

Coronary Disease: 36 US clinical trials tracked, 1 recruiting.

Coronary Disease is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 10 of these trials.

Enrollment posture brief

Registry condition coronary-disease

OPEN 1 | RECR 3% | LATE 5 | EARLY 6 | RANK #419 | SPON 10

Nearest open-share peer: Acne Vulgaris (3% recruiting · 68 trials)

Dysphagia63.9%Cognition50%Huntington Disease50%Chronic Myeloid Leukemia38.9%Coronary Disease (this)3%
Open-enrollment share among volume-matched conditions near Coronary Disease

Coronary Disease lists 1 open slots (3% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Coronary Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Coronary Disease is recruiting below its size-band peers.

    1 of 36 indexed trials (2.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Coronary Disease research.

    National Heart, Lung, and Blood Institute (NHLBI) accounts for 10 of 36 trials (27.8%). 23 distinct sponsors appear on at least one study for this condition label.

  3. Typical Coronary Disease enrolment sits around 360 participants.

    Median target enrolment is 360 among the 35 trials that report a genuine target (sentinel values excluded). 6 of those (17.1%) plan for fewer than 100 participants.

  4. Coronary Disease splits between interventional and observational designs.

    20 interventional and 16 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 26Phase 35

Open and recent trials

36 total, page 1 of 1

RECRUITING NA 5,000 participants

Evaluating New Radiation Techniques for Cardiovascular Imaging

National Heart, Lung, and Blood Institute (NHLBI)

NCT01621594

ACTIVE NOT RECRUITING 11,737 participants

Bogalusa Heart Study

Tulane University

NCT00005129

ACTIVE NOT RECRUITING 6,340 participants

University of North Carolina Alumni Heart Study

Duke University

NCT00005398

ACTIVE NOT RECRUITING 5,888 participants

Cardiovascular Health Study (CHS)

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005133

ACTIVE NOT RECRUITING 5,306 participants

The Jackson Heart Study of Cardiovascular Disease Among African Americans

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005485

ACTIVE NOT RECRUITING 2,314 participants

Mediators of Atherosclerosis in South Asians Living in America

University of California, San Francisco

NCT01207167

ACTIVE NOT RECRUITING 105 participants

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

Johns Hopkins University

NCT02694094

COMPLETED Phase 3 10,251 participants

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

National Heart, Lung, and Blood Institute (NHLBI)

NCT00000620

COMPLETED NA 5,179 participants

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

NYU Langone Health

NCT01471522

COMPLETED 5,034 participants

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

Abbott Medical Devices

NCT01120379

COMPLETED Phase 3 2,136 participants

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

Duke University

NCT00023595

COMPLETED NA 1,500 participants

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

Stanford University

NCT02100722

COMPLETED 1,395 participants

Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])

Northwestern University

NCT00626379

COMPLETED Phase 3 1,100 participants

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Pfizer

NCT00134173

COMPLETED Phase 3 911 participants

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

Tufts Medical Center

NCT00091507

COMPLETED 715 participants

Heart Rate Variability and Sudden Cardiac Death

Columbia University

NCT00005235

COMPLETED 650 participants

Comparison of Two Methods to Diagnose Coronary Artery Disease

Johns Hopkins University

NCT00063531

COMPLETED Phase 2 389 participants

Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery

Duke University

NCT00041392

COMPLETED Phase 2 360 participants

MRI Evaluation of Chest Pain

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001961

COMPLETED 324 participants

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

University of Washington

NCT00880178

COMPLETED Phase 2 309 participants

Estrogen, HDL, and Coronary Heart Disease in Women

Tufts University

NCT00083824

COMPLETED NA 287 participants

Collaborative Cardiac Care Project

US Department of Veterans Affairs

NCT00105664

COMPLETED NA 250 participants

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

Baylor Research Institute

NCT00224809

COMPLETED 213 participants

Detection of Coronary Artery Calcification: Comparison of Volumetric and Electron Beam Computed Tomography

National Institutes of Health Clinical Center (CC)

NCT00001836

COMPLETED 209 participants

Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001461

COMPLETED Phase 3 200 participants

Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle

National Heart, Lung, and Blood Institute (NHLBI)

NCT00001891

COMPLETED NA 170 participants

Sapphire 3 CTO Study

OrbusNeich

NCT06358508

COMPLETED 125 participants

Atherosclerosis in the Coronary and Carotid Arteries

National Heart, Lung, and Blood Institute (NHLBI)

NCT00080587

COMPLETED Phase 2 110 participants

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

Marc Sakwa, MD

NCT01681095

COMPLETED 45 participants

Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests

Corewell Health East

NCT00541203

COMPLETED NA 31 participants

Time Restricted Feeding for Weight Loss and Cardio-protection

University of Illinois at Chicago

NCT02948517

COMPLETED Phase 2 25 participants

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005928

COMPLETED Phase 2 25 participants

Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease

National Heart, Lung, and Blood Institute (NHLBI)

NCT00014040

COMPLETED NA 12 participants

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

Abbott Medical Devices

NCT02229864

COMPLETED 10 participants

Platelet Activation Markers in Pediatric Cardiac Surgery

Weill Medical College of Cornell University

NCT00450151

COMPLETED NA

Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women

National Center for Research Resources (NCRR)

NCT00000108

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 5

Named interventions

Most-linked intervention names on Coronary Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
Estrogens, Conjugated (USP) Drug
1 trials
Dobutamine echocardiography Procedure
1 trials
Myocardial contrast echocardiography Procedure
1 trials
Nitric Oxide and INOpulse Delivery System Drug
1 trials
Cold Blood Cardioplegia Drug
1 trials
Custodiol HTK Drug
1 trials
Resolute Onyx Stent Device
1 trials

US sites by state

Facility locations filed on Coronary Disease trials. A trial with sites in several states counts in each.

Maryland 12 trials
California 9 trials
North Carolina 6 trials
Washington 5 trials
Minnesota 5 trials
Michigan 5 trials
Texas 4 trials
Pennsylvania 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Coronary Disease page

36 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Disease condition card totals 36 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.